» Articles » PMID: 23098090

Clinical Aspects of Palliative Care in Advanced Parkinson's Disease

Overview
Publisher Biomed Central
Specialty Critical Care
Date 2012 Oct 27
PMID 23098090
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative disorders of the elderly population. Few therapeutic options are available for patients with PD requiring palliative care. Treatment of the early stages of PD is entirely different from later stages. During the later stages, the palliative care model is introduced to provide the patient with comfort and support. Early palliative care in PD requires minimization of dyskinesias and decreasing occurrence of motor and non-motor off times in an effort to maximize independent motor function. In the later stages, the focus of treatment shifts to treating the predominant non-motor symptoms and having a more supportive and palliative nature. The purpose of this review is to provide a summary of the palliative care management issues and palliative care management options of end-stage PD patients.

Citing Articles

Therapeutic singing-induced swallowing exercise for dysphagia in advanced-stage Parkinson's disease.

Yeo M, Hwang J, Lee H, Kim S, Cho S Front Neurol. 2024; 15:1323703.

PMID: 38628693 PMC: 11018993. DOI: 10.3389/fneur.2024.1323703.


Apomorphine at the End-of-Life-A Role to Play.

Azoia C, Borges C, Velon A, Raimundo R Mov Disord Clin Pract. 2023; 10(12):1827-1829.

PMID: 38094651 PMC: 10715338. DOI: 10.1002/mdc3.13907.


End of life care of hospitalized patients with Parkinson disease: a retrospective analysis and brief review.

Bhansali S, Assaedi E, Yu J, Mandava N, Sonneborn C, Hogue O Front Aging Neurosci. 2023; 15:1265156.

PMID: 37744391 PMC: 10511646. DOI: 10.3389/fnagi.2023.1265156.


Palliative Care of End Stage Parkinsonism: An Overview Including the Five Pillars Framework.

Hvisdak V, Huang A, Kluger B Mov Disord Clin Pract. 2023; 10(Suppl 2):S63-S67.

PMID: 37637979 PMC: 10448122. DOI: 10.1002/mdc3.13620.


The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.

Huang X, Lewis M, Jodi Van Scoy L, De Jesus S, Eslinger P, Arnold A J Parkinsons Dis. 2020; 10(4):1515-1527.

PMID: 32986682 PMC: 8640973. DOI: 10.3233/JPD-202188.


References
1.
Thomas S, Macmahon D . Parkinson's disease, palliative care and older people: Part 1. Nurs Older People. 2004; 16(1):22-6. DOI: 10.7748/nop2004.03.16.1.22.c2290. View

2.
Lees A, Blackburn N, Campbell V . The nighttime problems of Parkinson's disease. Clin Neuropharmacol. 1988; 11(6):512-9. DOI: 10.1097/00002826-198812000-00004. View

3.
Mena I, COTZIAS G . Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med. 1975; 292(4):181-4. DOI: 10.1056/NEJM197501232920404. View

4.
Aarsland D, Larsen J, Lim N, Janvin C, Karlsen K, Tandberg E . Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999; 67(4):492-6. PMC: 1736593. DOI: 10.1136/jnnp.67.4.492. View

5.
Aarsland D, Andersen K, Larsen J, Lolk A, Kragh-Sorensen P . Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003; 60(3):387-92. DOI: 10.1001/archneur.60.3.387. View